We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
CorMedix Inc | AMEX:CRMD | AMEX | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 8.90 | 0 | 01:00:00 |
Delaware
|
20-5894890
|
(State or other jurisdiction of incorporation or
organization)
|
(I.R.S. Employer Identification No.)
|
Large accelerated
filer
|
☐
|
Accelerated
filer
|
☐
|
|
|
|
|
Non-accelerated
filer
|
☐
|
Smaller reporting
company
|
☑
|
|
|
|
|
Emerging growth
company
|
☐
|
|
|
Title of each
class of
securities to be
registered
|
Amount to be
registered
(1)
|
Proposed maximum
aggregate offering price per unit
(2)
|
Proposed
maximum
aggregate
offering price
|
Amount of
registration
fee
|
Common stock,
$0.001 par value per share
|
14,990,585
|
$
1.50
|
$
22,485,877.50
|
$
2,725.29
|
About this
Prospectus
|
1
|
Special Note Regarding Forward-Looking Statements
|
2
|
Prospectus Summary
|
3
|
The Offering
|
4
|
Risk Factors
|
5
|
Use of Proceeds
|
5
|
Determination of Offering Price
|
5
|
Dilution
|
5
|
Selling Stockholders
|
6
|
Plan of Distribution
|
9
|
Dividend Policy
|
10
|
Description of Our Capital Stock
|
11
|
Certain Provisions of Delaware Law and of Our Amended and Restated
Certificate of Incorporation and Amended and Restated
Bylaws
|
18
|
Legal Matters
|
19
|
Experts
|
19
|
Where You Can Find Additional Information
|
19
|
Incorporation of Documents by Reference
|
19
|
|
|
|
|
PROSPECTUS SUMMARY
The following summary is qualified in its entirety by, and should
be read together with, the more detailed information and financial
statements and related notes thereto appearing elsewhere or
incorporated by reference in this prospectus and any prospectus
supplement. Before you decide to invest in our securities, you
should read the entire prospectus and any prospectus supplement
carefully, including the risk factors and the financial statements
and related notes set forth in and incorporated by reference in
this prospectus and any prospectus supplement.
Overview
We are
a
biopharmaceutical company
focused on developing and commercializing therapeutic products for
the prevention and treatment of infectious and inflammatory
diseases
.
Our
primary focus is to develop our lead product candidate,
Neutrolin
®
, for potential
commercialization in the U.S. and other key markets. We have
in-licensed the worldwide rights to develop and commercialize
Neutrolin, which is a novel anti-infective solution (a formulation
of taurolidine, citrate and heparin 1000 u/ml) under development in
the U.S. for the reduction and prevention of catheter-related
infections and thrombosis in patients requiring central venous
catheters in clinical settings such as dialysis, critical/intensive
care, and oncology. Infection and thrombosis represent key
complications among dialysis, critical care/ intensive care and
cancer patients with central venous catheters. These complications
can lead to treatment delays and increased costs to the healthcare
system when they occur due to hospitalizations, the need for IV
antibiotic treatment, long-term anticoagulation therapy,
removal/replacement of the central venous catheter, related
treatment costs and increased mortality. We believe Neutrolin has
the potential to address a significant unmet medical need and
represents a significant market opportunity.
In July
2013, we received CE Mark approval for Neutrolin. In
December 2013, we commercially launched Neutrolin in Germany
for the prevention of catheter-related bloodstream infections and
maintenance of catheter patency in hemodialysis patients using a
tunneled, cuffed central venous catheter for vascular
access. To date, Neutrolin is registered and may be sold
in certain European Union and Middle Eastern countries for such
treatment. In April 2017, we entered into a commercial
collaboration with Hemotech SAS covering France and French overseas
territories.
We
initiated our LOCK-IT 100 Phase 3 clinical trial in hemodialysis
patients with a central venous catheter in December 2015. Two
successful pivotal trials to demonstrate the safety and
effectiveness of Neutrolin generally are required by the U.S. Food
and Drug Administration, or FDA, to secure marketing approval in
the United States.
In
April 2017, a safety review by an independent Data Safety
Monitoring Board, or DSMB, was completed. The DSMB unanimously
concluded that it was safe to continue the LOCK-IT-100 clinical
trial as designed based on its evaluation of data from the first
279 patients randomized into the trial. On July 25, 2018, we
announced that the DSMB had completed its review of the interim
analysis of the data from the LOCK-IT-100 study and, because the
pre-specified level of statistical significance was reached and
efficacy had been demonstrated, the DSMB recommended the study be
terminated early.
We are
sponsoring a pre-clinical research collaboration for the use of
taurolidine as a possible combination treatment for rare orphan
pediatric tumors. In February 2018, the FDA granted orphan drug
designation to taurolidine for the treatment of neuroblastoma. We
are seeking one or more strategic partners or other sources of
capital to help us develop and commercialize taurolidine for the
treatment of neuroblastoma.
We are
also evaluating opportunities for the possible expansion of
taurolidine as a platform compound for use in certain medical
devices. Patent applications have been filed in wound closure,
surgical meshes, wound management, and osteoarthritis, including
visco-supplementation. Based on initial
feasibility work, we are advancing pre-clinical studies for
taurolidine-infused surgical meshes, suture materials, and
hydrogels. We will seek to establish development/commercial
partnerships as these programs advance.
The FDA
recently informed us that it regards taurolidine as a new chemical
entity and therefore an unapproved drug. Consequently, there is no
appropriate predicate device currently marketed in the U.S. on
which a 510k approval process could be based. As a result, we will
be required to submit a premarket approval application for
marketing authorization for these indications. In the event that
the New Drug Application for Neutrolin is approved by the FDA, the
regulatory pathway can be revisited with the FDA. Although
there will presumably still be no appropriate
predicate,
de
novo
Class II designation can be proposed, based on a
risk assessment and a reasonable assurance of safety and
effectiveness.
In August 2017, we secured a research grant from the National
Institutes of Health, or NIH, to expand our antimicrobial hydrogel
medical device program. In addition to our ongoing
development of taurolidine-incorporated hydrogels to reduce
infections in common burns, this funding will be applied toward the
development of an advanced hydrogel formulation that is designed to
reduce the risk of potentially life-threatening infection and
promote healing of more severe burn injuries, for which there is
significant need.
Corporate History and Information
We were organized as a Delaware
corporation on July 28, 2006 under the name “Picton Holding
Company, Inc.” and we changed our corporate name to
“CorMedix Inc.” on January 18, 2007. Our operations to
date have been primarily limited to
conducting clinical
trials and establishing manufacturing for our product candidates,
licensing product candidates, business and financial planning,
research and development, seeking regulatory approval for our
products, initial commercialization activities for Neutrolin in the
European Union and other foreign markets, and maintaining and
improving our patent portfolio.
Our
executive offices are located at 400 Connell Drive, Suite 5000,
Berkeley Heights, NJ 07922. Our telephone number is (908) 517-9500.
Our website address is www.cormedix.com. Information contained in,
or accessible through, our website does not constitute part of this
report.
|
|
|
|
|
|
|
|
|
THE OFFERING
This
prospectus relates to the resale by the selling stockholders
identified in this prospectus of up to 14,990,585 shares of our
common stock issuable upon the exercise of the following
warrants:
●
Series
B warrants for 13,873,426 shares of common stock issued to
investors in our May 2017 underwritten public offering, with an
exercise price of $1.05 per share that expire on August 10, 2022;
and
●
Underwriter
warrants for 1,117,159 shares issued in our May 2017 underwritten
public offering, with an exercise price of $0.9375 per share that
expire on August 10, 2022.
|
|
|
|
|
|
Common
stock offered by the selling stockholders
|
14,990,585
shares
|
|
|
Common
stock outstanding before the offering
(1)
|
98,827,056
shares
|
|
|
Common
stock to be outstanding after the offering
(2)
|
113,817,641
shares
|
|
|
Common
stock NYSE American Symbol
|
CRMD
|
|
Selling Stockholder
|
Number of Shares
of Common Stock Beneficially Owned Before Any Sale
(1)
|
%
of
Class
|
Number of Shares
of Common Stock Offered
|
Shares of Common
Stock Beneficially Owned After Sale of All Shares of Common Stock
Pursuant to this Prospectus
(2)
|
|
|
|
|
|
Number of
Shares
|
%
of
Class
|
Series
B Warrants issued in May 2017
|
|
|
|
|
|
Sabby
Healthcare Master Fund, Ltd.
|
2,574,999
|
2.54
%
|
2,574,999
|
-0-
|
*
|
Sabby
Volatility Warrant Master Fund, Ltd.
|
1,275,000
|
1.27
%
|
1,275,000
|
-0-
|
*
|
CVI
Investments, Inc.
|
2,850,000
|
2.80
%
|
2,850,000
|
-0-
|
*
|
Hudson
Bay Master Fund Ltd.
|
6,650,000
|
6.54
%
|
2,850,000
|
3,800,000
|
3.74
%
|
Elliott Associates LP
(3)
|
10,506,114
|
9.99
%
|
640,000
|
10,506,114
|
9.99
%
|
Elliott International LP
(3)
|
10,506,114
|
9.99
%
|
1,360,001
|
10,506,114
|
9.99
%
|
TMB
Pacific Global LLC
|
14,581
|
*
|
6,249
|
8,332
|
*
|
Brian
Herman
|
21,875
|
*
|
9,375
|
12,500
|
*
|
Eli
Goldschmidt
|
8,750
|
*
|
3,750
|
5,000
|
*
|
Thomas
J. Guerin IRA
|
88,795
|
*
|
38,055
|
50,740
|
*
|
Mark
Winkler Mark Winkler Appraisal SEP-IRA
|
19,999
|
*
|
8,571
|
11,428
|
*
|
Bill
Compton/Sally C. Compton Jt. Ten/WROS
|
35,000
|
*
|
15,000
|
20,000
|
*
|
Geisha
Alomar/Lynn Tirado Jt. Ten/WROS
|
35,000
|
*
|
15,000
|
20,000
|
*
|
Loren
Estad
|
35,000
|
*
|
15,000
|
20,000
|
*
|
Russel
Malsam
|
19,250
|
*
|
8,250
|
11,000
|
*
|
Brian
Wolf
|
22,137
|
*
|
9,487
|
12,650
|
*
|
The
Kimball Fund
|
22,138
|
*
|
9,488
|
12,650
|
*
|
Robert
E. Taylor
|
22,750
|
*
|
9,750
|
13,000
|
*
|
James
R. Niemann
|
21,000
|
*
|
9,000
|
12,000
|
*
|
Fox
Hollow Holdings Inc.
|
17,500
|
*
|
7,500
|
10,000
|
*
|
Richard
Rosenblum
|
23,333
|
*
|
10,000
|
13,333
|
*
|
David
Shively
|
136,500
|
*
|
58,500
|
78,000
|
*
|
Fox
Run Investments LLC
|
17,500
|
*
|
7,500
|
10,000
|
*
|
Myra
C. Vazquez, Roth IRA
|
43,750
|
*
|
18,750
|
25,000
|
*
|
IMS
Group LLC
|
17,500
|
*
|
7,500
|
10,000
|
*
|
Peter
Lemus IRA
|
17,500
|
*
|
7,500
|
10,000
|
*
|
Ruth
A. Beisel Roth IRA
|
8,750
|
*
|
3,750
|
5,000
|
*
|
Nancy
Brody
|
22,750
|
*
|
9,750
|
13,000
|
*
|
Aujla
Mngmt Srvce Corp
|
17,500
|
*
|
7,500
|
10,000
|
*
|
Thomas
J. Loughlin
|
70,000
|
*
|
30,000
|
40,000
|
*
|
Arthur
Bregman
|
14,000
|
*
|
6,000
|
8,000
|
*
|
Donald
A. Johnson
|
25,200
|
*
|
10,800
|
14,400
|
*
|
Robert
J. Costantino
|
161,000
|
*
|
69,000
|
92,000
|
*
|
Avila
Family Trust Dtd. 7/23/09 Humberto Avila and Tesse Avila
Ttees.
|
52,500
|
*
|
22,500
|
30,000
|
*
|
Jonathan
Steinhouse
|
14,000
|
*
|
6,000
|
8,000
|
*
|
Jonathan
Steinhouse R/O IRA
|
17,500
|
*
|
7,500
|
10,000
|
*
|
Mordechai
Vogel
|
23,333
|
*
|
10,000
|
13,333
|
*
|
Orlando
Santa Cruz IRA
|
246,519
|
*
|
105,651
|
140,868
|
*
|
Jimmie
H. Harvey
|
46,550
|
*
|
19,950
|
26,600
|
*
|
James
E. Cantrell Jr.
|
233,333
|
*
|
100,000
|
133,333
|
*
|
Michael
G. Lindley
|
233,333
|
*
|
100,000
|
133,333
|
*
|
POC
Capital LLC
|
23,275
|
*
|
9,975
|
13,300
|
*
|
Gary A. Gelbfish
(4)
|
3,952,619
|
3.93
%
|
1,000,000
|
2,952,619
|
2.93
%
|
Scott
F. Ansell
|
23,334
|
*
|
10,000
|
13,334
|
*
|
Jason
Chalecki
|
23,333
|
*
|
10,000
|
13,333
|
*
|
Wolcot
Capital Inc.
|
35,000
|
*
|
15,000
|
20,000
|
*
|
John
J. Ewine
|
280,350
|
*
|
120,150
|
160,200
|
*
|
Gary
L. Gottschalk Living Trust
|
133,350
|
*
|
57,150
|
76,200
|
*
|
James
Reitzner
|
65,100
|
*
|
27,900
|
37,200
|
*
|
Brent
W. Hoag
|
84,000
|
*
|
36,000
|
48,000
|
*
|
Paul
E. Linthorst IRA
|
28,875
|
*
|
12,375
|
16,500
|
*
|
James
G. Newsome Jr.
|
10,500
|
*
|
4,500
|
6,000
|
*
|
Michael
R. Pate
|
52,500
|
*
|
22,500
|
30,000
|
*
|
Larry
Brandon R/O IRA
|
106,750
|
*
|
45,750
|
61,000
|
*
|
Nathaniel
Orme
|
14,000
|
*
|
6,000
|
8,000
|
*
|
Robert
Lumbardo and Desiree M. Lumbardo JTWROS
|
336,000
|
*
|
144,000
|
192,000
|
*
|
Timothy
C. Davis
|
45,500
|
*
|
19,500
|
26,000
|
*
|
|
|
|
|
|
|
Underwriter
Warrants issued in May 2017
|
|
|
|
|
|
OTA LLC
(5)
|
340,733
|
*
|
340,733
|
-0-
|
*
|
Noam
Rubinstein
(5)
|
351,905
|
*
|
351,905
|
-0-
|
*
|
Warberg WF V
LP
|
150,000
|
*
|
150,000
|
-0-
|
*
|
Warberg WF VI
LP
|
150,000
|
*
|
150,000
|
-0-
|
*
|
Option
Opportunities Corp.
|
62,261
|
*
|
62,261
|
-0-
|
*
|
Serenity Now
LLC
|
62,260
|
*
|
62,260
|
-0-
|
*
|
TOTAL
|
32,013,884
|
23.90
%
|
14,990,585
|
19,023,300
|
14.20
%
|
(1)
|
Except
as otherwise disclosed, consists of (i) shares of common stock
and (ii) the shares of common stock issuable upon the exercise of
the warrants, which warrant shares are offered hereby.
|
(2)
|
Assumes
that each selling stockholder will sell all of its shares of common
stock issuable upon the exercise of their warrants subject to sale
pursuant to this prospectus, although in the individual line items
we give effect to only the individual sale of that designated
number of shares.
|
(3)
|
Due to
the Ownership Limitation (as defined below), Elliott Associates,
L.P. (“Elliott Associates”) may be deemed the
beneficial owner of 10,506,114 shares of our common stock through
securities held by it and by Manchester Securities Corp., a
wholly-owned subsidiary of Elliott Associates
(“Manchester”), and Elliott International, L.P.
(“Elliott International”), the investment advisor of
which is an affiliate of the investment advisor of Elliott
Associates. Elliott Associates beneficially holds: (i) 2,833,470
shares of our common stock held by Elliott International, (ii)
1,333,398 shares of our common stock held by Elliott Associates,
(iii) May 2013 warrants held by Manchester exercisable for 500,000
shares of our common stock, (iv) 52,500 shares of our Series C-2
non-voting convertible preferred stock held by Elliott Associates
convertible into 525,000 shares of our common stock, (v) October
2013 warrants held by Elliott Associates exercisable for 262,500
shares of our common stock, (vi) 97,500 shares of our Series C-2
non-voting convertible preferred stock held by Elliott
International convertible into 1,500,000 shares of our common
stock, (vii) October 2013 warrants held by Elliott International
exercisable for 487,500 shares of our common stock, (viii) 73,962
shares of our Series D non-voting convertible preferred stock held
by Manchester convertible into 1,479,240 shares of our common
stock, (ix) March 2015 Warrants held by Manchester convertible into
200,000 shares of our common stock, (x) May 2017 Series B warrants
held by Elliott International convertible into 1,360,001 shares of
our common stock, (xi) May 2017 Series B warrants held by Elliott
Associates convertible into 640,000 shares of our common stock,
(xii) 89,623 shares of our Series E non-voting convertible
preferred stock held by Manchester convertible into 1,959,759
shares of our common stock, (xiii) 1,360 shares of our Series F
non-voting convertible preferred stock held by Elliott
International convertible into 8,395,062 shares of our common stock
(subject to adjustment), (xiv) 640 shares of our Series F
non-voting convertible preferred stock held by Elliott Associates
convertible into 3,950,617 shares of our common stock (subject to
adjustment), (xv) November 2017 warrants exercisable for 384,103
shares of our common stock held by Elliott International, and (xvi)
November 2017 warrants exercisable for 180,755 shares of our common
stock held by Elliott Associates (the May 2013 warrants, the
October 2013 warrants, the March 2015 Warrants, the May 2017 Series
B warrants, the November 2017 warrants and all shares of preferred
stock shall collectively be referred to herein as the
“Convertible Securities”). However, in accordance with
Rule 13d-4 under the Exchange Act, the number of shares of our
common stock into which the Convertible Securities are convertible
or exercisable, as applicable, are limited pursuant to the terms of
the Convertible Securities to that number of shares of our common
stock which would result in Elliott Associates having aggregate
beneficial ownership of, with respect to the May 2013 warrants, the
October 2013 warrants, the March 2015 Warrants, the May 2017 Series
B warrants, the November 2017 warrants, the Series C-2 preferred
stock, the Series D preferred stock, the Series E preferred stock
and the Series F preferred stock, 9.99% of the total issued and
outstanding shares of our common stock (the "Ownership
Limitation"). Elliott Associates disclaims beneficial ownership of
any and all shares of our common stock issuable upon any conversion
or exercise of the Convertible Securities if such conversion or
exercise would cause Elliott Associates’ aggregate beneficial
ownership to exceed or remain above the applicable Ownership
Limitation (as is currently the case). Therefore, Elliott
Associates disclaims beneficial ownership of any shares of our
common stock, issuable upon any conversion or exercise of the May
2013 warrants, the October 2013 warrants, the March 2015 Warrants,
the May 2017 Series B warrants, the November 2017 warrants, the
Series C-2 preferred stock, the Series D preferred stock, the
Series E preferred stock and the Series F preferred stock, which
conversion of exercise would be prohibited by the Ownership
Limitation. The business address of Elliott Associates is 40 West
57th Street, 30th Floor, New York, New York 10019. Based solely on
information contained in a Schedule 13D filed with the SEC on
November 13, 2017 by Elliott Associates and other information known
to us.
|
(4)
|
Consists
of (i) 2,106,954 shares of our common stock, (ii) 14,000 shares of
our common stock held indirectly, (iii) 79,999 shares of our common
stock issuable upon the exercise of stock options, (iv) 1,666
shares of our common stock upon issuance of restricted stock units,
(v) 500,000 shares of common stock upon conversion of Series C-3
non-voting preferred stock, and (vi) 1,250,000 shares of common
stock issuable upon exercise of warrants.
|
(5)
|
The
selling stockholder is an affiliate of a registered
broker-dealer.
|
SEC registration
fee
|
$
2,725
|
Legal fees and
expenses
|
20,000
*
|
Accounting fees and
expenses
|
15,000
*
|
Printing
expenses
|
5,000
*
|
Miscellaneous
|
2,275
*
|
Total
|
45,000
*
|
Exhibit
Number
|
|
Description of
Document
|
|
Registrant’s
Form
|
|
Dated
|
|
Exhibit
Number
|
|
Filed
Herewith
|
|
At
Market Issuance Sales Agreement, dated March 9, 2018, between
CorMedix Inc. and B. Riley FBR, Inc.
|
|
S-3
|
|
3/09/2018
|
|
1.1
|
|
|
|
|
Form of
Amended and Restated Certificate of Incorporation.
|
|
S-1/A
|
|
3/01/2010
|
|
3.3
|
|
|
|
|
Certificate
of Amendment to Amended and Restated Certificate of Incorporation,
dated February 24, 2010.
|
|
S-1/A
|
|
3/19/2010
|
|
3.5
|
|
|
|
|
Form of
Amended and Restated Bylaws as amended April 19, 2016.
|
|
10-Q
|
|
5/10/2016
|
|
3.1
|
|
|
|
|
Certificate
of Amendment to Amended and Restated Certificate of Incorporation,
dated December 3, 2012.
|
|
10-K
|
|
3/27/2013
|
|
3.3
|
|
|
|
|
Certificate
of Amendment to Amended and Restated Certificate of Incorporation,
dated August 9, 2017.
|
|
8-K
|
|
8/10/2017
|
|
3.1
|
|
|
|
|
Certificate
of Designation of Series A Non-Voting Convertible Preferred Stock
of CorMedix Inc., filed with the Delaware Secretary of State on
February 18, 2013, as corrected on February 19, 2013.
|
|
8-K
|
|
2/19/2013
|
|
3.3
|
|
|
|
|
Certificate
of Designation of Series B Non-Voting Convertible Preferred Stock
of CorMedix Inc., filed with the Delaware Secretary of State on
July 26, 2013.
|
|
8-K
|
|
7/26/2013
|
|
3.4
|
|
|
|
|
Certificate
of Designation of Series C-1 Non-Voting Convertible Preferred Stock
of CorMedix Inc., filed with the Delaware Secretary of State on
October 21, 2013.
|
|
8-K
|
|
10/23/2013
|
|
3.5
|
|
|
|
|
Amended
and Restated Certificate of Designation of Series C-2 Non-Voting
Convertible Preferred Stock of CorMedix Inc., filed with the
Delaware Secretary of State on September 15, 2014.
|
|
8-K
|
|
9/16/2014
|
|
3.15
|
|
|
|
|
Amended
and Restated Certificate of Designation of Series C-3 Non-Voting
Convertible Preferred Stock of CorMedix Inc., filed with the
Delaware Secretary of State on September 15, 2014.
|
|
8-K
|
|
9/16/2014
|
|
3.16
|
|
|
|
|
Amended
and Restated Certificate of Designation of Series D Non-Voting
Convertible Preferred Stock of CorMedix Inc., filed with the
Delaware Secretary of State on September 15, 2014.
|
|
8-K
|
|
9/16/2014
|
|
3.17
|
|
|
|
|
Amended
and Restated Certificate of Designation of Series E Non-Voting
Convertible Preferred Stock of CorMedix Inc., filed with the
Delaware Secretary of State on September 15, 2014.
|
|
8-K
|
|
9/16/2014
|
|
3.18
|
|
|
|
|
Amended
and Restated Certificate of Designation of Series F Non-Voting
Convertible Preferred Stock of CorMedix Inc., filed with the
Delaware Secretary of State on December 11, 2017.
|
|
8-K
|
|
12/11/2017
|
|
3.1
|
|
|
|
|
Specimen
of Common Stock Certificate.
|
|
S-1/A
|
|
3/19/2010
|
|
4.1
|
|
|
|
|
Form of
Warrant issued on February 19, 2013.
|
|
8-K
|
|
2/19/2013
|
|
4.13
|
|
|
|
|
Form of
Warrant issued to ND Partners on April 11, 2013.
|
|
10-Q
|
|
5/15/2013
|
|
4.18
|
|
|
|
|
Form of
Warrant issued on July 30, 2013.
|
|
8-K
|
|
7/26/2013
|
|
4.21
|
|
|
|
|
Form of
Warrant issued on October 22, 2013.
|
|
8-K
|
|
10/18/2013
|
|
4.22
|
|
|
|
|
Form of
Warrant issued on January 8, 2014.
|
|
8-K
|
|
1/09/2014
|
|
4.23
|
|
|
|
|
Form of
Warrant issued on March 10, 2014
|
|
8-K
|
|
03/05/2014
|
|
4.24
|
|
|
|
|
Warrant
issued March 3, 2015.
|
|
8-K
|
|
03/04/2015
|
|
4.1
|
|
|
|
|
Amended
and Restated Warrant originally issued March 24, 2010.
|
|
8-K
|
|
03/04/2015
|
|
4.2
|
|
|
|
|
Amended
and Restated Warrant originally issued May 30, 2013.
|
|
8-K
|
|
03/04/2015
|
|
4.3
|
|
|
|
|
Registration
Rights Agreement, dated March 3, 2015, by and between CorMedix Inc.
and Manchester Securities Corp.
|
|
8-K
|
|
03/04/2015
|
|
4.5
|
|
|
|
|
Form
of Series A Warrant to Purchase Common Stock of CorMedix Inc.
issued on May 3, 2017.
|
|
8-K
|
|
5/03/2017
|
|
4.1
|
|
|
|
|
Form
of Series B Warrant to Purchase Common Stock of CorMedix Inc.
issued on May 3, 2017.
|
|
8-K
|
|
5/03/2017
|
|
4.2
|
|
|
|
|
Form
of Underwriter’s Warrant to Purchase Common Stock of CorMedix
Inc., issued May 3, 2017.
|
|
8-K
|
|
5/03/2017
|
|
4.3
|
|
|
|
|
Form
of Warrant issued on November 16, 2017.
|
|
8-K
|
|
11/13/2017
|
|
4.15
|
|
|
|
5.1
|
|
Opinion
of Wyrick Robbins Yates & Ponton LLP.
|
|
|
|
|
|
|
|
|
23.1
|
|
Consent
of Friedman LLP, Independent Registered Accounting
Firm.
|
|
|
|
|
|
|
|
x
|
23.3
|
|
Consent
of Wyrick Robbins Yates & Ponton LLP (included as part of
Exhibit 5.1).
|
|
|
|
|
|
|
|
x
|
24.1
|
|
Power
of Attorney (included in the signature page hereto).
|
|
|
|
|
|
|
|
x
|
|
CORMEDIX
INC.
|
|
|
|
|
|
|
|
By:
|
/s/
Khoso Baluch
|
|
|
|
Khoso Baluch |
|
|
|
Chief Executive Officer |
|
Signature
|
|
Capacity
|
|
Date
|
|
|
|
|
|
/s/ Khoso
Baluch
|
|
Director
and Chief Executive Officer (Principal Executive
Officer)
|
|
October
15, 2018
|
Khoso
Baluch
|
|
|
|
|
|
|
|
|
|
/s/ Robert
Cook
|
|
Chief
Financial Officer (Principal Fiancial Officer and Principal
Accounting Officer)
|
|
October 15,
2018
|
Robert
Cook
|
|
|
|
|
|
|
|
|
|
/s/
Janet Dillione
|
|
Director
|
|
October 15,
2018
|
Janet
Dillione
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
October [__],
2018
|
Gary
Gelbfish
|
|
|
|
|
|
|
|
|
|
/s/
Steven Lefkowitz
|
|
Director
|
|
October 15,
2018
|
Steven
Lefkowitz
|
|
|
|
|
|
|
|
|
|
/s/
Myron Kaplan
|
|
Director
|
|
October 15,
2018
|
Myron
Kaplan
|
|
|
|
|
|
|
|
|
|
/s/
Mehmood
Khan
|
|
Director
|
|
October 15,
2018
|
Mehmood
Khan
|
|
|
|
|
|
|
|
|
|
1 Year CorMedix Chart |
1 Month CorMedix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions